Schwab International Equity ETF™
Most Recent
Analyzing the Possible Impacts of the Iran Deal Exit
President Trump’s decision to withdraw from the Joint Comprehensive Plan of Action (or JCPOA) could lead to regional conflicts in the Middle East.
Novartis in 2Q17: Performance of Alcon
For 2Q17, Alcon reported a 1.0% growth in revenues to $1.52 billion compared to $1.51 billion in 2Q16.
Novartis’s 2Q17 Estimates: How Sandoz Might Perform
Revenues for Sandoz are expected to report operational growth in 2Q17 following an increased demand for biopharmaceuticals.
Novartis Stock in 2Q17: How Has It Performed?
A look at Novartis Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company specializing in the research, development, manufacturing, and marketing of a broad range of healthcare products, mainly pharmaceuticals. The company has segregated its business into three segments: Innovative Medicines, Sandoz (generic), and Alcon (eye care). Stock price performance Novartis’s stock price has […]
Inside Novartis’s Innovative Medicines Segment in 1Q17
Novartis’s (NVS) Innovative Medicines segment contributed ~67% of NVS’s total revenues in 1Q17.
GlaxoSmithKline’s Pharmaceuticals Segment in 1Q17
The Pharmaceuticals segment reported an operational growth of 4.0% and a 13.0% positive impact of foreign exchange, resulting in a rise of 17.0% in revenues.
How AstraZeneca’s Growth Platforms Performed in 1Q17
A few of the segments AstraZeneca identifies as growth platforms include Respiratory products, new Cardiovascular and Metabolic Diseases products, and new Oncology products.
Performance of Sanofi Genzyme in 1Q17
Sanofi (SNY) reported growth of over 15% at constant exchange rates in its 1Q17 revenues from Genzyme.
Novartis’s 1Q17 Earnings: Recent Developments
On January 6, 2017, Novartis announced the collaborative agreement with Ionis Pharmaceuticals (IONS) and its subsidiary Akcea Therapeutics.
How Does Novartis’s Valuation Compare to Peers?
On January 13, 2017, Novartis was trading at a forward PE multiple of ~15.1x.
Performance of GSK’s Global Pharmaceuticals Franchises Mixed
The global pharmaceuticals franchise is GlaxoSmithKline’s (GSK) largest revenue contributor.
Why an Unmoved Bank of Japan in April Shook Up Japanese Equities
Haruhiko Kuroda, governor of the Bank of Japan, loves to give surprises. In his latest attempt, he left the monetary stance of the Bank of Japan unchanged on April 28, 2016.
Understanding the Fall in Toyota Motor’s Sales in 2015
Toyota Motor’s stock has technically broken support and was trading below all moving day averages on January 21.
